
													
															
															Year
															DEALS // DEV.
															Country
															
															Therapeutic Area
															Study Phase
															Deal Type
															Product Type
															Dosage Form
															Lead Product
															Target

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : PEP08
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : PharmaEngine
Deal Size : Inapplicable
Deal Type : Inapplicable
PharmaEngine's Novel PRMT5 Inhibitor PEP08 Receives Clinical Trial Approvals
Details : PEP08 is a next-generation PRMT5 inhibitor small molecule drug candidate, which is being evaluated for the treatment of solid tumors.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 09, 2025
Lead Product(s) : PEP08
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : PharmaEngine
Deal Size : Inapplicable
Deal Type : Inapplicable

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Technology
Study Phase : Discovery Platform
Sponsor : Pfizer Inc
Deal Size : Undisclosed
Deal Type : Expanded Collaboration
XtalPi and Pfizer Expand Strategic Collaboration to Advance AI-Driven Drug Discovery
Details : XtalPi and Pfizer expanded their partnership to enhance AI-driven molecular modeling, aiming to accelerate drug discovery of small molecules with improved accuracy and efficiency.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
June 29, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Technology
Highest Development Status : Discovery Platform
Sponsor : Pfizer Inc
Deal Size : Undisclosed
Deal Type : Expanded Collaboration

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery
Sponsor : Incendia Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
XtalPi and Parthenon Enter into AI-Powered Antibody Discovery Partnership
Details : Under this agreement, XtalPi will grant Parthenon Therapeutics access to its proprietary XupremAb™ antibody discovery platform, which is a collection of solutions that leverage AI and wet lab techniques to deliver therapeutic antibody candidates.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
September 05, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery
Sponsor : Incendia Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Technology
Study Phase : Discovery Platform
Sponsor : Eli Lilly
Deal Size : $250.0 million
Deal Type : Collaboration
Details : The collaboration will leverage XtalPi's integrated AI capabilities and robotics platform including, ID4Inno™ small-molecule drug discovery platform, to de novo design and deliver drug candidates for an undisclosed target.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
May 30, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Technology
Highest Development Status : Discovery Platform
Sponsor : Eli Lilly
Deal Size : $250.0 million
Deal Type : Collaboration

XtalPi and EDDC Collaborate In AI-Empowered Drug Discovery Program for Non-Small Cell Lung Cancer
Details : Under the collaboration, XtalPi joins forces with EDDC to apply its AI technology, automation platform, and expert domain knowledge to discover promising candidates against a NSCLC target chosen by EDDC.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
December 19, 2022

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Sponsor : CK Life Sciences
Deal Size : Undisclosed
Deal Type : Collaboration
Details : XtalPi and CK Life Sciences will leverage their respective expertise to jointly develop a novel AI tumour vaccine R&D platform to improve the discovery and design capabilities of tumour vaccines and accelerate the development of more vaccine types.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
November 24, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Sponsor : CK Life Sciences
Deal Size : Undisclosed
Deal Type : Collaboration

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Technology
Study Phase : Discovery
Sponsor : GSK
Deal Size : Undisclosed
Deal Type : Collaboration
XtalPi Announces Research Collaboration with Janssen
Details : Under the agreement, XtalPi will deliver validated small molecule hits that possess defined properties for a given target nominated by Janssen. XtalPi will deploy its comprehensive, end-to-end platform – Inclusive Digital Drug Discovery & Development (...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
October 27, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Technology
Highest Development Status : Discovery
Sponsor : GSK
Deal Size : Undisclosed
Deal Type : Collaboration
